The role of glatiramer acetate in the early treatment of multiple sclerosis

David W BrandesHope MS Center, Knoxville, TN, USA; ULCA, Los Angeles, CA, USAAbstract: The treatment of the underlying disease process causing multiple sclerosis has continued to evolve since the initial approval of interferon-beta-1b in 1993. Current emphasis is on early treatment, including treatm...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	David W Brandes
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/61356ac105164c298ae585332c41ab39
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:61356ac105164c298ae585332c41ab39
record_format	dspace
spelling	oai:doaj.org-article:61356ac105164c298ae585332c41ab392021-12-02T04:08:53ZThe role of glatiramer acetate in the early treatment of multiple sclerosis1176-63281178-2021https://doaj.org/article/61356ac105164c298ae585332c41ab392010-06-01T00:00:00Zhttp://www.dovepress.com/the-role-of-glatiramer-acetate-in-the-early-treatment-of-multiple-scle-a4565https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021David W BrandesHope MS Center, Knoxville, TN, USA; ULCA, Los Angeles, CA, USAAbstract: The treatment of the underlying disease process causing multiple sclerosis has continued to evolve since the initial approval of interferon-beta-1b in 1993. Current emphasis is on early treatment, including treatment after a single clinical attack (clinically isolated syndrome). The assessment of which disease modifying medication to use as initial therapy has continued to remain a combination of science and the art of medicine. Equally important are the assessment of treatment failure and the subsequent choice of medication change. This article will present scientific information, as well as information about clinical decision making, about these choices, with emphasis on the changing role of glatiramer acetate in this process.Keywords: glatiramer acetate, early treatment, multiple sclerosis David W BrandesDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2010, Iss Issue 1, Pp 329-336 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 David W Brandes The role of glatiramer acetate in the early treatment of multiple sclerosis
description	David W BrandesHope MS Center, Knoxville, TN, USA; ULCA, Los Angeles, CA, USAAbstract: The treatment of the underlying disease process causing multiple sclerosis has continued to evolve since the initial approval of interferon-beta-1b in 1993. Current emphasis is on early treatment, including treatment after a single clinical attack (clinically isolated syndrome). The assessment of which disease modifying medication to use as initial therapy has continued to remain a combination of science and the art of medicine. Equally important are the assessment of treatment failure and the subsequent choice of medication change. This article will present scientific information, as well as information about clinical decision making, about these choices, with emphasis on the changing role of glatiramer acetate in this process.Keywords: glatiramer acetate, early treatment, multiple sclerosis
format	article
author	David W Brandes
author_facet	David W Brandes
author_sort	David W Brandes
title	The role of glatiramer acetate in the early treatment of multiple sclerosis
title_short	The role of glatiramer acetate in the early treatment of multiple sclerosis
title_full	The role of glatiramer acetate in the early treatment of multiple sclerosis
title_fullStr	The role of glatiramer acetate in the early treatment of multiple sclerosis
title_full_unstemmed	The role of glatiramer acetate in the early treatment of multiple sclerosis
title_sort	role of glatiramer acetate in the early treatment of multiple sclerosis
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/61356ac105164c298ae585332c41ab39
work_keys_str_mv	AT davidwbrandes theroleofglatirameracetateintheearlytreatmentofmultiplesclerosis AT davidwbrandes roleofglatirameracetateintheearlytreatmentofmultiplesclerosis
_version_	1718401432800985088

The role of glatiramer acetate in the early treatment of multiple sclerosis

Ejemplares similares